key: cord-0996332-i3h4kdax
authors: Capetti, Amedeo F.; Borgonovo, Fabio; Mileto, Davide; Gagliardi, Gloria; Mariani, Chiara; Lupo, Angelica; Dedivitiis, Gianfranco; Meraviglia, Paola; Pellicciotta, Martina; Armiento, Luciana; Cossu, Maria V.; Rizzardini, Giuliano
title: One-year durability of anti-spike IgG to SARS-CoV-2: preliminary data from the AntiCROWN prospective observational study One year durability of COVID-19 anti-spike IgG
date: 2021-05-27
journal: J Infect
DOI: 10.1016/j.jinf.2021.05.023
sha: d5aa08d7f4356af9ee41d108ba8ab73e811091da
doc_id: 996332
cord_uid: i3h4kdax

Data are presented of 368/503 post-COVID-19 outpatients followed within the AntiCROWN Cohort who have a one-year control and a baseline assessment of anti-S1/S2 antibodies, detected with the The LIAISON® SARS-CoV-2 S1/S2 IgG solution by DiaSorin. Loss of response occurred in 4 subjects having a baseline level below 50 AU/mL.

Keywords antibodies, COVID-19, durability, spike, coronavirus, observational Dear Editor, we read with interest the article by Ross J Harris and colleagues 1 , showing assay-dependent durability of antibodies to SARS-CoV-2 after 6 months of symptomatic and asymptomatic COVID-19 as assessed by five different immunoassays with a prediction of durability at one year. We present our preliminary data on DiaSorin anti S1/S2 IgG production after one year from disease onset or detection of SARS-CoV-2 infection. The AntiCROWN study is being run in an hospital-based outpatient clinic open to all people who have serological or PCR evidence of SARS-Cov-2 infection. On May 13, 2020, the Infectious Diseases Department of Luigi Sacco Hospital, Milan, Italy, started an outpatient clinic for the follow-up of COVID-19 patients, diagnosed by a positive nasopharyngeal swab or a combination of clinical and epidemiological criteria and a positive serological test. Only patients whose onset was dated between February 20 and April 30, 2020 are included in this analysis (the so called "first wave"). The LIAISON® SARS-CoV-2 S1/S2 IgG solution (DiaSorin, Saluggia, Italy) used to quantify the antibody response shows a positive agreement of 94.4% (88.8% -97.2%) with in vitro neutralising antibody titre 2 . The response was tested at the first outpatient visit (T1) set at week 12 ± 3 weeks from symptoms onset or diagnosis in asymptomatic subjects, at T2 (20 ± 3 weeks), T3 (32 ± 3 weeks) and T4 (52 ± 3 weeks). Since December, 2020, we were imposed a ceiling cut-off of 400 AU/mL. According to the WHO classification for COVID-19 severity patients were divided into mild, moderate, severe and critical 3 . We calculated the relative risk of falling < 15 Arbitrary Units (AU)/mL with 95% confidence interval and statistical significance according to Altman and the significance of decay or increase over time through the Mann-Whitney and Wilcoxon log-rank test. The study was approved by the "Comitato Etico Interaziendale Area 1″. All patients signed a written informed consent. The full ARCOVID cohort counts 1048 outpatients, of whom 503 from the 'first wave'. We present preliminary data of 368 patients who had a one-year control of serum anti-S1/S2 IgG levels (11 to 14 months, median 12.5 months). Our patients belonged to all severity classes according to the WHO definition. However, since response better correlated with baseline antibody production, we used this criterion to analyse data presented in Table 1 , stratifying by <15 (positive cut-off value), 15-50 (arbitrary cut-off for low antibody production) and >50 AU/mL. The mean age was 58.9 years (range 4-92 years) and 174 (41.8%) were females. Immune suppression or immune depression (HIV infection, cancer, immune diseases and autoimmunity, steroids, anti-cancer chemotherapy, monoclonal anti-B lymphocyte drugs) were present in patients. Our data suggest that loss of anti-S1/S2 IgG response at one year may be a rare event, occurring only in subjects who produce less than 50 AU/mL within the initial 4 months since disease onset. Of note, 12 patients had unexpected increase of antibody production in the absence of vaccination 

Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers

LIAISON Ⓡ SARS-CoV-2 S1/S2 IgG The fully automated serology test for the detection of SARS CoV-2

World Health Organization. Clinical Management of COVID-19

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine

Bringing together evidence to tackle COVID-19

World Health Organization. Coronavirus disease (COVID-19) Advice for the public

We thank Simona Bocchio for her silent but substantial help in dealing with patients, visits and with the general organization of the clinic. No contribution was received for this study.